Page last updated: 2024-08-25

voacamine and Epithelial Ovarian Cancer

voacamine has been researched along with Epithelial Ovarian Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Condello, M; Gallo, FR; Meschini, S; Multari, G; Pellegrini, E; Vecchiotti, D; Zazzeroni, F	1

Other Studies

1 other study(ies) available for voacamine and Epithelial Ovarian Cancer

Article	Year
A natural product, voacamine, sensitizes paclitaxel-resistant human ovarian cancer cells. Toxicology and applied pharmacology, 2022, 01-01, Volume: 434 Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Ibogaine; Molecular Structure; Ovarian Neoplasms; Paclitaxel	2022

Article

Year

A natural product, voacamine, sensitizes paclitaxel-resistant human ovarian cancer cells.

Toxicology and applied pharmacology, 2022, 01-01, Volume: 434

Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Ibogaine; Molecular Structure; Ovarian Neoplasms; Paclitaxel

2022